Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
CD.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.439	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.439	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.408	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.408	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.256	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.256	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
Q.7 (Alpha)	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
Q.7 (Alpha)	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.460	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.460	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.262	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.262	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
AY.43.6 (Delta)	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
AY.43.6 (Delta)	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XBF.4	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XBF.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.27	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.2.27	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
AY.43.9 (Delta)	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
AY.43.9 (Delta)	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XU	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XU	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.144	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.144	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.288	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.288	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.249	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.249	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.378	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.378	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.97	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.97	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.9	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.9	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
CS.1	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-17982.1	US
CS.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.83	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.2.83	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BJ.1	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BJ.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XDG	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XDG	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GA.4	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
GA.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
KD.1	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
KD.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.2.11	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.5.2.11	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.53	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used